コンテンツへスキップ
Merck
  • Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans.

Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans.

Blood (2014-05-14)
Ryan Flynn, Jing Du, Rachelle G Veenstra, Dawn K Reichenbach, Angela Panoskaltsis-Mortari, Patricia A Taylor, Gordon J Freeman, Jonathan S Serody, William J Murphy, David H Munn, Stefanie Sarantopoulos, Leo Luznik, Ivan Maillard, John Koreth, Corey Cutler, Robert J Soiffer, Joseph H Antin, Jerome Ritz, Jason A Dubovsky, John C Byrd, Kelli P MacDonald, Geoff R Hill, Bruce R Blazar
要旨

Chronic graft-versus-host disease (cGVHD) is a leading cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Having shown that germinal center (GC) formation and immunoglobulin deposition are required for multiorgan system cGVHD and associated bronchiolitis obliterans syndrome (BOS) in a murine model, we hypothesized that T follicular helper (Tfh) cells are necessary for cGVHD by supporting GC formation and maintenance. We show that increased frequency of Tfh cells correlated with increased GC B cells, cGVHD, and BOS. Although administering a highly depletionary anti-CD20 monoclonal antibody (mAb) to mice with established cGVHD resulted in peripheral B-cell depletion, B cells remained in the lung, and BOS was not reversed. BOS could be treated by eliminating production of interleukin-21 (IL-21) by donor T cells or IL-21 receptor (IL-21R) signaling of donor B cells. Development of BOS was dependent upon T cells expressing the chemokine receptor CXCR5 to facilitate T-cell trafficking to secondary lymphoid organ follicles. Blocking mAbs for IL-21/IL-21R, inducible T-cell costimulator (ICOS)/ICOS ligand, and CD40L/CD40 hindered GC formation and cGVHD. These data provide novel insights into cGVHD pathogenesis, indicate a role for Tfh cells in these processes, and suggest a new line of therapy using mAbs targeting Tfh cells to reverse cGVHD.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
アセトン, ACS reagent, ≥99.5%
Sigma-Aldrich
アセトン, suitable for HPLC, ≥99.9%
Sigma-Aldrich
アセトン, HPLC Plus, for HPLC, GC, and residue analysis, ≥99.9%
Sigma-Aldrich
アセトン, Laboratory Reagent, ≥99.5%
Sigma-Aldrich
アセトン, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.5% (GC)
Sigma-Aldrich
アセトン, suitable for HPLC, ≥99.8%
Sigma-Aldrich
フルオロセイン 5(6)-イソチオシアナート, BioReagent, suitable for fluorescence, mixture of 2 components, ≥90% (HPLC)
Sigma-Aldrich
アセトン, ACS reagent, ≥99.5%
Sigma-Aldrich
フルオロセインイソチオシアナート, アイソマー I, suitable for protein labeling, ≥90% (HPLC), powder
USP
アセトン, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
アセトン, JIS special grade, ≥99.5%
Sigma-Aldrich
アセトン, histological grade, ≥99.5%
Sigma-Aldrich
アセトン, puriss., meets analytical specification of Ph. Eur., BP, NF, ≥99% (GC)
Sigma-Aldrich
アセトン, natural, ≥97%
Sigma-Aldrich
アセトン, SAJ first grade, ≥99.0%
Sigma-Aldrich
フルオロセイン 5(6)-イソチオシアナート, ≥90% (HPLC)
Sigma-Aldrich
アセトン, ≥99%, meets FCC analytical specifications
Sigma-Aldrich
フルオロセインイソチオシアナート, アイソマー I, ≥97.5% (HPLC)
Supelco
アセトン, analytical standard
Sigma-Aldrich
フルオロセインイソチオシアナート, アイソマー I, ≥97.5% (HPLC)
Sigma-Aldrich
アセトン, ≥99.5%, for residue analysis
Supelco
アセトン, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
アセトン, for residue analysis, ≥99.5%
Sigma-Aldrich
アセトン, for chromatography, ≥99.8%
Sigma-Aldrich
アセトン, for residue analysis, JIS 5000
Sigma-Aldrich
アセトン, suitable for HPLC, ≥99.9%
Sigma-Aldrich
アセトン, suitable for HPLC